Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. RESULTS: Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1-positive and PD-L1-negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. CONCLUSIONS: Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies examining the clinical activity of single agent anti-PD-1/PD-L1 therapies in the neoadjuvant setting have reported MPR rates between 19% and 45% in patients with resectable NSCLC14–16.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, studies of neoadjuvant immunotherapy in patients with resectable NSCLC reported responses irrespective of PD-L114,21,”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Items 601–700 of 1,000
Wang, Y., Li, C., Wang, Z., Wang, Z., Wu, R., Wu, Y., Song, Y., & Liu, H. (2022) · BMC Medicine · doi:10.1186/s12916-022-02580-1 · Cited by 33
“checkmate159 [24] 2021 nivo 2 22 20 22 23% 4.”
Liu, W., Ren, S., Yang, L., Xiao, Y., Zeng, C., Chen, C., Wu, F., & Hu, Y. W. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000650 · Cited by 33
“New potential biomarkers, including the T-cell receptor repertoire [6,22] , tumor-in fi ltrating lymphocytes [23] , immune gene signature [24] , and gut microbial-derived metabolites [25] , are being investigated with interesting results, but are in the preclinical stage.”
BackgroundXia, W.-Y., Feng, W., Zhang, C., Shen, Y., Zhang, Q., Yu, W. J., Cai, X., & Fu, X. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-827 · Cited by 32
“published a prospective phase II trial evaluating the safety and feasibility of nivolumab induction in resectable NSCLC (25).”
BackgroundNeoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
Shukla, N. A., & Hanna, N. H. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s277717 · Cited by 34
Zhai, W.-Y., Duan, F., Lin, Y., Lin, Y., Zhao, Z.-R., Wang, J., Rao, B.-Y., Zheng, L., & Long, H. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s418276 · Cited by 31
“MPR is defined as the presence of no more than 10% residual cancer cells within the primary tumor bed, which is same as the Checkmate 159 study.(28)”
BackgroundDickhoff, C., Otten, R. H. J., Heymans, M. W., & Dahele, M. R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918804150 · Cited by 28
Chen, J. A., Ma, W., Yuan, J. D., & Li, T. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_9 · Cited by 31
Tobias, J., Battin, C., Linhares, A. D. S., Lebens, M., Baier, K., Ambroz, K., Drinić, M., Högler, S., Inić‐Kanada, A., Garner‐Spitzer, E., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00895 · Cited by 28
Immunotherapy in Myeloproliferative Diseases
Braun, L. M., & Zeiser, R. (2020) · Cells · doi:10.3390/cells9061559 · Cited by 37
“Since PD-1 blockade was shown to expand mutation-associated, antigen-specific tumor-reactive T-cell clones in the peripheral blood in lung cancer patients, it was hypothesized that immune checkpoint blockade could be beneficial to combine with anti-tumor vaccines to enhance the anti-leukemia immune response [6,178].”
BackgroundPerioperative considerations for neoadjuvant immunotherapy in non–small cell lung cancer
Stiles, B. M., Sepesi, B., Broderick, S., & Bott, M. J. (2020) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2020.05.119 · Cited by 32
Self-citationTian, Y., Xu, J., Chu, Q., Duan, J., Zhang, J. J., Bai, H., Yang, Z., Fang, W., Cai, L., Wan, R., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01694-8 · Cited by 30
Self-citationSesma, A., Pardo, J., Cruellas, M., Gálvez, E. M., Ruiz, M. G., Isla, D., Martínez‐Lostao, L., Ocáriz, M., Paño, J. R., Quílez, E., et al. (2020) · Cancers · doi:10.3390/cancers12102974 · Cited by 28
Dong, N., Moreno‐Manuel, A., Fariñas, S. C., Gallach, S., Zhang, F., Blasco, A., Aparisi, F., Meri-Abad, M., Guijarro, R., Sirera, R., et al. (2021) · Cancers · doi:10.3390/cancers13122950 · Cited by 29
“Nonetheless, results from limited reports focused on the characterization of peripheral blood TCR repertoire and response prediction are variable, perhaps due to the small sample size, differences in tumor types, sequencing methods or the type of ICB used [25,27,37,40].”
BackgroundGross, E. E., Li, M., Yin, M., Orcutt, D. J., Hussey, D., Trott, E., Holt, S. K., Dwyer, E. R., Kramer, J. H., Oliva, K., et al. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.08.013 · Cited by 33
The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
Dibajnia, P., Cardenas, L. M., & Lalani, A. A. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2178217 · Cited by 32
A surgically optimized intraoperative poly(I:C)-releasing hydrogel prevents cancer recurrence
Rwandamuriye, F. X., Evans, C. W., Wylie, B., Nörret, M., Vitali, B., Ho, D., Nguyen, D., Roper, E. A., Wang, T., Hepburn, M. S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101113 · Cited by 33
Neoadjuvant Immunotherapy: A Promising New Standard of Care
Boydell, E., Sandoval, J. L., Michielin, O. A., Obéid, M., Addeo, A., & Friedlaender, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411849 · Cited by 33
“In one patient in CHECKMATE-159, T cell clones specific for tumour neoantigens were expanded in their lymph nodes and peripheral blood after neoadjuvant nivolumab, supporting the hypothesis that neoadjuvant immunotherapy can generate a systemic immune response capable of eradicating micrometastases [22].”
BackgroundMethodInfluentialPathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy
Weissferdt, A., Leung, C. H., Lin, H. Y., Sepesi, B., William, W. N., Swisher, S. G., Cascone, T., Lee, J. J., & Pataer, A. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100353 · Cited by 30
Pulliam, T. H., Jani, S., Jing, L., Ryu, H., Jojic, A., Shasha, C., Zhang, J., Kulikauskas, R. M., Church, C. D., Garnett‐Benson, C., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101412 · Cited by 29
Self-citationSchoenfeld, J. D., Gjini, E., Rodig, S. J., Tishler, R. B., Rawal, B., Catalano, P. J., Uppaluri, R., Haddad, R. I., Hanna, G. J., Chau, N. G., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.05.002 · Cited by 28
Lian, W., Jiang, D., Lin, W., Jiang, M., Zhang, Y., Wang, H. Z., & Zhao, L. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87440 · Cited by 27
“Mechanistically, effective ICB therapies mainly depends on CD8 + T cells [6-8].”
BackgroundSelf-citationGBM immunotherapy: Exploring molecular and clinical frontiers
Ghosh, M. K., Kumar, S., Begam, S., Ghosh, S., & Basu, M. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123018 · Cited by 30
Hamada, A., Soh, J., Hata, A., Nakamatsu, K., Shimokawa, M., Yatabe, Y., Oizumi, H., Tsuboi, M., Horinouchi, H., Yoshino, I., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.04.006 · Cited by 29
Saqi, A., Leslie, K. O., Moreira, A. L., Lantuéjoul, S., Shu, C. A., Rizvi, N. A., Sonett, J. R., Tajima, K., Sun, S. W., Gitlitz, B. J., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100310 · Cited by 45
“Recent clinical trials of neoadjuvant checkpoint inhibitors included patients with stages I to IIIA NSCLC.6,8,23 Although potentially resectable, a stage IIIA NSCLC tumor may exceed 7 cm in diameter.”
BackgroundMethodInfluentialCheng, J., Guo, M., Yang, Y., Liu, Y., Hu, W., Shang, Q., Li, C., Xia, L., Wang, Y., Wang, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848881 · Cited by 27
“Despite the fact that patients are more likely to benefit from neoadjuvant immunotherapy compared with traditional neoadjuvant therapy (15, 16), the safety and efficacy of immunotherapy for locally advanced, surgically resectable esophageal cancer has not been evaluated comprehensively yet.”
BackgroundBredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 29
Self-citationMetformin as a booster of cancer immunotherapy
Panaampon, J., Zhou, Y., & Saengboonmee, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110528 · Cited by 31
Yang, G., Su, X., Huang, Y., Luo, G., Wang, Z., Cai, P., Zheng, Y., Bei, T., Huang, M., Bai, Y., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04273-6 · Cited by 31
“In addition, neoadjuvant use of PD-1 blockade in combination with chemotherapy has also shown favorable antitumor efficacy in several malignancies, including lung [11, 12] and colorectal cancers [13, 14].”
BackgroundFerrarotto, R., Nagarajan, P., Maronge, J. M., Johnson, J. M., Rosenthal, D. I., Myers, J. N., & Gross, N. D. (2023) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2023.1729 · Cited by 29
Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges
O’Leary, C. L., Pierce, N., Patel, S. P., & Naidoo, J. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.11.018 · Cited by 36
Self-citationBandini, S., Ulivi, P., & Rossi, T. (2024) · Cells · doi:10.3390/cells13040337 · Cited by 29
“Different cancer types, including melanoma, non-small-cell lung cancer, renal cell carcinoma, and breast cancer [5–9], have demonstrated sustained clinical response rates.”
BackgroundResectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment
Brascia, D., Iaco, G. D., Schiavone, M., Panza, T., Signore, F., Geronimo, A., Sampietro, D., Montrone, M., Galetta, D., & Marulli, G. (2020) · Cancers · doi:10.3390/cancers12082050 · Cited by 27
Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
Liu, Y., Xu, C., Han, X., Cheng, X., Jiang, S., Lin, Y., Zhang, Z., Lu, L., Qu, B., Chen, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032747 · Cited by 31
“In 2018, a pilot study reported that neoadjuvant nivolumab therapy resulted in a major pathological response (MPR) of 45% and the response was corre la ted with TMB (83) .”
BackgroundInfluentialWu, X., Chau, Y. F., Bai, H., Zhuang, X., Wang, J., & Duan, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1099304 · Cited by 28
“Previous studies have proved that major pathological response (MPR) defined as no more than 10% viable tumor in resected specimen could be a better predictor of overall survival than overall response rate (14, 15).”
BackgroundResultInfluentialParisi, C., Abdayem, P., Tagliamento, M., Besse, B., Planchard, D., Remón, J., Minuti, G., Cappuzzo, F., & Barlési, F. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102845 · Cited by 34
Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies
Pignot, G., Loriot, Y., Kamat, A. M., Shariat, S. F., & Plimack, E. R. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.01.002 · Cited by 28
Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma
Behrens, C., Rocha, P., Parra, E. R., Feng, L., Rodriguez‐Canales, J., Solis, L. M., Mino, B., Zhang, J. J., Gibbons, D. L., Sepesi, B., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.003 · Cited by 27
Self-citationImmuno-Oncology for Esophageal Cancer
Yamamoto, S., & Kato, K. (2020) · Future Oncology · doi:10.2217/fon-2020-0545 · Cited by 31
Modulation of the Vascular-Immune Environment in Metastatic Cancer
He, B., & Ganß, R. (2021) · Cancers · doi:10.3390/cancers13040810 · Cited by 28
“In contrast, immunotherapy with checkpoint inhibitor anti‐ bodies such as anti‐programmed cell death protein‐1 (PD‐1) (Nivolumab) and an‐ ti‐cytotoxic T lymphocyte antigen‐4 (CTLA‐4) (Ipilimumab) seems to induce stronger anti‐tumor immunity as post‐surgical (adjuvant) therapy in patients with resectable metastatic mel…”
BackgroundBeyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines
Roesler, A. S., & Anderson, K. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_35 · Cited by 27
Gao, Y., Jiang, J., Xiao, D., Zhou, Y., Chen, Y., Yang, H., Wang, L., Zeng, J., He, B., He, R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.969545 · Cited by 29
International expert consensus on immunotherapy for early-stage non-small cell lung cancer
on behalf of CATO consensus group, Liang, W., Cai, K., Cao, Q., Chen, C., Chen, H., Chen, J., Chen, K., Chen, Q., Chu, T., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-617 · Cited by 28
“Recent phase II studies on neoadjuvant immunotherapy (23,32,34,36,64,65) showed that the incidence of adverse events of any grade caused by neoadjuvant single-agent immunotherapy was 23–62%, the incidence of grade 3 or higher adverse events was 4.”
BackgroundMethodResultInfluentialSelf-citationHaddad, R. I., Massarelli, E., Lee, J. J., Lin, H. Y., Hutcheson, K. A., Lewis, J., Garden, A. S., Blumenschein, G. R., William, W. N., Pharaon, R. R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy549 · Cited by 26
Liquid biopsy in newly diagnosed patients with locoregional (I-IIIA) non-small cell lung cancer
Chen, K., Kang, G., Zhao, H., Zhang, K., Zhang, J., Yang, F., & Wang, J. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1599717 · Cited by 32
“patients is still under exploration [3,4].”
BackgroundSelf-citationPeng, H., Zhang, Y., Zhou, Z., Guo, Y., Huang, X., Westover, K. D., Zhang, Z., Chen, B., Hua, Y., Li, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.002 · Cited by 27
Risk-based stratification in head and neck mucosal melanoma
Moya‐Plana, A., Mangin, D., Dercle, L., Taouachi, R., Casiraghi, O., Ammari, S., Nguyen, F., Temam, S., Robert, C., & Gorphe, P. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.07.026 · Cited by 26
Zeng, J., Yi, B., Chang, R., Chen, Y., Yu, Z., & Gao, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1134713 · Cited by 25
“Patients without viable tumor cells in resected lymph nodes and primary lung cancer were defined as pCR, while less than 10% of viable tumor cells were defined as MPR, and more than 10% were defined as an incomplete pathological response (IPR) (12). frontiersin.org”
BackgroundSun, C., Wang, X., Xu, Y., Shao, G., Chen, X., Liu, Y., Zhang, P., Lin, X., Ma, X., Qiu, S., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102422 · Cited by 26
“Published trials 23,24 have reported MPR rates ranging from 19% to 45% in monotherapy with neoadjuvant immunotherapy and 50% in dual ICI therapy.”
BackgroundCurrent Status of Immunotherapy for Lung Cancer and Future Perspectives
Kim, H. C., & Choi, C. (2019) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2019.0039 · Cited by 29
Kozono, D., Stinchcombe, T. E., Salama, J. K., Bogart, J. A., Petty, W. J., Guarino, M. J., Bazhenova, L. A., Larner, J. M., Weiss, J., DiPetrillo, T. A., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.028 · Cited by 25
Clarke, J. M., Patel, J. D., Robert, F., Kio, E. A., Thara, E., Camidge, D. R., Dunbar, M., Nuthalapati, S., Dinh, M. H., & Bach, B. A. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.09.004 · Cited by 25
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
Mielgo-Rubio, X., Montemuiño, S., Jiménez, U., Luna, J., Cardeña-Gutiérrez, A., Mezquita, L., Martín, M., & Couñago, F. (2021) · Cancers · doi:10.3390/cancers13194811 · Cited by 35
“CheckMate-159 [47] I Safety I–IIIA (33%) 91% Nivolumab 3 mg/kg/2 w × 2 cycles None 5% 15% 18%”
BackgroundKönig, D., Schär, S., Vuong, D., Gückenberger, M., Furrer, K., Opitz, I., Weder, W., Rothschild, S. I., Ochsenbein, A. F., Zippelius, A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100455 · Cited by 29
“2) Smoking burden (pack-years) - median (min, max) 45 (3-182) Histological subtype, n (%) - Adenocarcinoma 166 (38.”
Aguado, C., Chara, L. E., Antoñanzas, M., Matilla-González, J. M., Jiménez, U., Hernánz, R., Mielgo-Rubio, X., Trujillo-Reyes, J. C., & Couñago, F. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i5.314 · Cited by 32
Deng, H., Liang, H., Chen, J., Wang, W., Li, J., Xiong, S., Cheng, B., Li, C., Chen, Z., Wang, H., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-439 · Cited by 32
“Notably, two to four treatment cycles were administrated in most of the relevant phase II/III trials on neoadjuvant immunotherapy (15-17, 20, 21 ) .”
Self-citationZhuang, F., Haoran, E., Huang, J., Wu, J., Xu, L., Zhang, L., Li, Q., Li, C., Zhao, Y., Yang, M., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.02.001 · Cited by 25
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 33
Cheng, B., Li, C., Li, J., Gong, L., Liang, P., Chen, Y., Zhan, S., Xiong, S., Zhong, R., Liang, H., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01799-z · Cited by 26
“9,28,43 Additionally, several investigations demonstrated that higher TCR diversity was associated with superior response to anti-PD-1/PD-L1 therapy, 29,42,44 whereas Zhang et al. reported a converse fi nding that patient with lower TCR diversity achieved better bene fi t from immunotherapy.”
Self-citationTasaki, M., YAMASHITA, M., Arai, Y., Nakamura, T., & Nakao, S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02947-y · Cited by 25
Zhao, D., Li, H., Mambetsariev, I., Mirzapoiazova, T., Chen, C., Fricke, J., Kulkarni, P., Villaflor, V., Arvanitis, L., Hamilton, S., et al. (2022) · Cancers · doi:10.3390/cancers14194933 · Cited by 24
“Furthermore, ICIs before or after surgery showed efficacy in patients with resectable disease in neoadjuvant and adjuvant settings, highlighting the potential of ICIs to improve outcomes in this patient group [20,21].”
BackgroundPan, H., Zou, N., Tian, Y., Zhu, H., Zhang, J., Jin, W., Gu, Z., Ning, J., Li, Z., Kong, W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228451 · Cited by 27
Self-citationCui, P., Li, J., Tao, H., Li, X., Wu, L., Ma, J., Wang, H., Liu, T., Zhang, M., & Hu, Y. (2023) · Oncogene · doi:10.1038/s41388-023-02805-4 · Cited by 28
“The incidence of CIP is approximately 3–5% according to clinical trial data [15, 16]; however, the occurrence of CIP can be higher in real-world settings than previously reported [17, 18].”
Self-citationThe immunotherapeutic landscape in non–small cell lung cancer and its surgical horizons
Rhodin, K. E., Rucker, A. J., Ready, N., D’Amico, T. A., & Antonia, S. J. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.08.138 · Cited by 24
ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth
Wang, Y., Luo, M., Chen, Y., Wang, Y., Zhang, B., Ren, Z., Bao, L., Wang, Y., Wang, J. E., Fu, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1710 · Cited by 24
Zhao, Z., Gao, Y., Xue, Q., Gao, S., & He, J. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00818-1 · Cited by 25
Surgery after Induction Targeted Therapy and Immunotherapy for Lung Cancer
Allaeys, T., Berzenji, L., & Schil, P. E. V. (2021) · Cancers · doi:10.3390/cancers13112603 · Cited by 25
“Furthermore, patients with a MPR had significantly higher rates of these T-cell clones [24].”
BackgroundLung Cancer Surgery after Neoadjuvant Immunotherapy
Stefani, D., Plönes, T., Viehof, J., Darwiche, K., Stuschke, M., Schüler, M., & Aigner, C. (2021) · Cancers · doi:10.3390/cancers13164033 · Cited by 26
“While a clinical paper on neoadjuvant chemoimmunotherapy in 2017 purely focused on immune profiling [44], the first trial on neoadjuvant immunotherapy alone was published by Forde in 2018 [31].”
Zhang, F., Qiu, B., Ji, Y., Guo, W., Li, N., Xue, Q., Gao, S., & He, J. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1007 · Cited by 27
Kiani, F. K., Izadi, S., Dezfouli, E. A., Ebrahimi, F., Mohammadi, M. K., Chalajour, H., Bulus, M. M., Esfahani, M. N., Karpisheh, V., Khesht, A. M. S., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120166 · Cited by 25
RetractedRocha, P., Zhang, J., Briviesca, R. L., Cruz‐Bermúdez, A., Bota‐Rabassedas, N., Sanchez-Espiridon, B., Yoshimura, K., Behrens, C., Lü, W., Tang, X., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3207 · Cited by 24
Self-citationGao, J., Zhang, L.-X., Ao, Y.-Q., Jin, C., Zhang, P., Wang, H., Wang, S., Lin, M., Jiang, J.-H., & Ding, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215774 · Cited by 26
Self-citationChen, Z., Fu, R., Tan, X., Yan, L., Tang, W., Qiu, Z., Qi, Y., Li, Y., Hou, Q., Wu, Y.-L. L. C., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14562 · Cited by 29
Cohen, I., Pareja, F. G., Socci, N. D., Shen, R., Doane, A. S., Schwartz, J., Khanin, R., Morris, E. A., Sutton, E. J., & Blasberg, R. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880959 · Cited by 26
Biomarkers of response to immunotherapy in early stage non-small cell lung cancer
Dugage, M. R., Albarrán-Artahona, V., Laguna, J. C., Chaput, N., Vignot, S., Besse, B., Mezquita, L., & Auclin, É. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.01.029 · Cited by 25
PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
Tang, Q., Zhao, S., Zhou, N., He, J., Zu, L., Liu, T., Song, Z., Chen, J., Peng, L., & Xu, S. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5497 · Cited by 32
“Postoperative complications occurred in 10 out of 20 patients (50%) and the most common was atrial arrhythmia (6/20; 30%) (39,40).”
BackgroundA Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer
Guo, N. L., Dowlati, A., Raese, R. A., Dong, C., Chen, G., Beer, D. G., Shaffer, J. S., Singh, S., Bokhary, U., Liu, L., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.05.025 · Cited by 24
“The synergy between PD-1 blockade and CD27 stimulation for CD8+T-cell driven anti-tumor immunity was reported recently [35], indicating the therapeutic potential of CD27 in neoadjuvant PD-1 blockade in resectable lung cancer [36].”
BackgroundThe Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies
Keung, E. Z.-Y., & Wargo, J. A. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.008 · Cited by 24
Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
Li, Z., Wu, X., Zhao, Y., Xiao, Y., Zhao, Y., Zhang, T., Li, H., Sha, F., Wang, Y., Deng, L., et al. (2021) · MedComm · doi:10.1002/mco2.61 · Cited by 23
Zhao, Y., Li, D., Zhuang, J., Li, Z., Xia, Q., Li, Z., Yu, J., Wang, J., Zhang, Y., Li, K., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1674 · Cited by 25
Liu, J., Xu, X., Zhong, H., Yu, M., Abuduaini, N., Zhang, S., Yang, X. Y., & Feng, B. (2024) · Biomedicines · doi:10.3390/biomedicines12071446 · Cited by 24
“The PD-L1 blockade drastically altered clinical cancer treatment and greatly boosted patients with cancer’s survival [21].”
BackgroundDong, H., Zhang, Z., Ni, M., Xu, X., Luo, Y., Wang, Y., Zhang, H., & Chen, J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01246-9 · Cited by 27
Sugiyama, K., Gordon, A., Popat, S., Okines, A. F. C., Larkin, J., & Chau, I. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104122 · Cited by 30
Lucia, A. D., Mazzotti, L., Gaimari, A., Zurlo, M., Maltoni, R., Cerchione, C., Bravaccini, S., Delmonte, A., Crinò, L., de Souza, P. B., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1515748 · Cited by 31
“…inhibitor 2A (CDKN2A), AT-Rich Interaction Domain 1A (ARID1A), Neurogenic locus notch homolog protein 1 (NOTCH1), myelocytomatosis oncogene (MYC), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), and retinoblastoma 1 (RB1) (204, 205).”
Lung cancer recurrence after neoadjuvant immunotherapy
Li, H., Pezeshkian, F., Xie, Y., Mazzola, E., Barcelos, R. R., Hooshmand, F., Han, T., Laaksonen, S., Sholl, L. M., Vega, C., et al. (2025) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2025.04.028 · Cited by 23
Raimondi, A., Randon, G., Sepe, P., Claps, M., Verzoni, E., de Braud, F., & Procopio, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174263 · Cited by 25
Kneuertz, P. J., Carbone, D. P., D’Souza, D. M., Shilo, K., Abdel‐Rasoul, M., Zhao, W., Williams, T. M., Jones, D. R., & Merritt, R. E. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.012 · Cited by 23
Self-citationRadiotherapy and Immunotherapy Combinations for Lung Cancer
Agrawal, V., Benjamin, K. T., & Ko, E. C. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00993-w · Cited by 23
Su, Y., Li, C.-C., Lin, Y., & Hsu, C. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730949 · Cited by 24
Surgical perspective in neoadjuvant chemoimmunotherapy for stage II – III non‐small cell lung cancer
Hong, T., Sun, T., Zhang, M., Liu, X., Yuan, Y., Dolo, P. R., Chen, B., & Zhang, H. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14127 · Cited by 23
“Many studies have been published on neoadjuvant therapy for NSCLC (Table 4): Checkmate-159 research showed that neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced MPR in 45% of resected tumors.(20) The NADIM study was the first to evaluate the potential therapeutic effect of…”
BackgroundMeta-Analysis of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer
Cao, C. Q., Le, A., Bott, M. J., Yang, C. J., Gossot, D., Melfi, F. M. A., Tian, D. H., & Guo, A. (2021) · Current Oncology · doi:10.3390/curroncol28060395 · Cited by 28
“0% 67 30 100% 12 17 1 0 0 4 3 23 0 Bott [12] Forde [13] 22 20 90.”
BackgroundMethodInfluentialPataer, A., Weissferdt, A., Correa, A. M., Vaporciyan, A. A., Sepesi, B., Heymach, J. V., Berezowska, S., Cascone, T., & Swisher, S. G. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100420 · Cited by 30
“Several immunotherapy-based neoadjuvant trials produced greater rates of CPR and MPR compared with chemotherapy in patients with operable NSCLC, which will enable investigators to prospectively evaluate the relationship between pathologic surrogate and survival outcomes,(3,4,29,30) and the addition of chemotherapy to…”
BackgroundFerro, A., Sepulcri, M., Schiavon, M., Scagliori, E., Mancin, E., Lunardi, F., Gennaro, G., Frega, S., Maso, A. D., Bonanno, L., et al. (2022) · Cancers · doi:10.3390/cancers14225700 · Cited by 29
Blakely, C. M., Weder, W., Bubendorf, L., He, J., Majem, M., Shyr, Y., & Chaft, J. E. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.01.002 · Cited by 25
Self-citationImmunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review
Montrone, M., Rosati, G., Longo, V., Catino, A., Massafra, R., Nardone, A., Pesola, F., Montagna, E. S., Marech, I., Pizzutilo, P., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051833 · Cited by 27
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
Chen, L. N., Wei, A. Z., & Shu, C. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231163798 · Cited by 23
“31 Interestingly, the authors also found that treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in the blood.”
BackgroundBao, X., Bian, D., Yang, X., Wang, Z., Shang, M., Jiang, G., & Shi, J. (2023) · European Radiology · doi:10.1007/s00330-023-09813-8 · Cited by 24
Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma
Hoeijmakers, L. L., Reijers, I. L. M., & Blank, C. U. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0352 · Cited by 28
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming
Luri‐Rey, C., Gomis, G., Glez‐Vaz, J., Manzanal, A., Riaño, A. M., Rodriguez-Ruiz, M. E., Teijeira, Á., & Melero, I. (2023) · Immunological Reviews · doi:10.1111/imr.13281 · Cited by 24
“49 The uptake of tumor antigen from cells undergoing cell death by dendritic cells, particularly cDC1, and its cross-presentation have been extensively described.”
BackgroundSaruwatari, K., Sato, R., Nakane, S., Sakata, S., Takamatsu, K., Jodai, T., Mito, R., Horio, Y., Saeki, S., Tomita, Y., et al. (2019) · Cancers · doi:10.3390/cancers11020140 · Cited by 25
“The mIHC analysis has been shown to capture multidimensional data related to tissue architecture, spatial distribution of multiple cell phenotypes, and co-expression of signaling [18,19].”
Zhou, C., & Zhang, J. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0685-9 · Cited by 24
Self-citation
Metadata
- Authors
- Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., Chan, H. Y., Sidhom, J.-W., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R., & Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Forde, Patrick M.
- Chaft, Jamie E.
- Smith, Kellie N.
- Anagnostou, Valsamo
- Cottrell, Tricia R.
- Hellmann, Matthew D.
- Zahurak, Marianna
- Yang, Stephen C.
- Jones, David R.
- Broderick, Stephen
- Velez, Moises J.
- Rekhtman, Natasha
- Naidoo, Jarushka
- Marrone, Kristen A.
- Verde, Franco
- Guo, Haidan
- Zhang, Jiajia
- Caushi, Justina X.
- Sidhom, John-William
- Scharpf, Robert B.
- White, James
- Wang, Hao
- Rosner, Gary L.
- Rusch, Valerie
- Wolchok, Jedd D.
- Merghoub, Taha
- Taube, Janis M.
- Velculescu, Victor E.
- Topalian, Suzanne L.
- Brahmer, Julie R.
- Pardoll, Drew M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-24
- Volume
- 378
- Issue
- 21
- Pages
- 1976-1986
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6223617
- OpenAlex
- W2798160602
- Cited by
- 2,099
- References
- 33
- Citations by year
- 2026: 123 · 2025: 181 · 2024: 241 · 2023: 304 · 2022: 304 · 2021: 342 · 2020: 279 · 2019: 214 · 2018: 110
- FWCI
- 89.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- International Association for the Study of Lung Cancer
- LUNGevity Foundation
- MacMillan Foundation
- Lung Cancer Foundation of America
- National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
- ECOG-ACRIN
- Commonwealth Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Bristol-Myers Squibb
- Bloomberg–Kimmel Institute for Cancer Immunotherapy
- Stand Up To Cancer (SU2C-AACR-DT1012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, nivolumab, resectable non-small cell lung cancer, early-stage lung cancer, pathological response, PD-L1 expression, tumor mutational burden, predictive biomarkers, treatment safety and feasibility
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pilot Projects, Neoadjuvant Therapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.